Cargando…
Predicting Response to Anthracyclines in Ovarian Cancer
(1) Background: Anthracyclines are intriguing drugs, representing one of the cornerstones of both first and subsequent-lines of chemotherapy in ovarian cancer (OC). Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. P...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998349/ https://www.ncbi.nlm.nih.gov/pubmed/35409939 http://dx.doi.org/10.3390/ijerph19074260 |
_version_ | 1784684921902596096 |
---|---|
author | Ferrero, Annamaria Borghese, Martina Restaino, Stefano Puppo, Andrea Vizzielli, Giuseppe Biglia, Nicoletta |
author_facet | Ferrero, Annamaria Borghese, Martina Restaino, Stefano Puppo, Andrea Vizzielli, Giuseppe Biglia, Nicoletta |
author_sort | Ferrero, Annamaria |
collection | PubMed |
description | (1) Background: Anthracyclines are intriguing drugs, representing one of the cornerstones of both first and subsequent-lines of chemotherapy in ovarian cancer (OC). Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. Prediction of response to anthracyclines is challenging and no markers can predict certain therapeutic success. The current narrative review provides a summary of the clinical and biological mechanisms involved in the response to anthracyclines. (2) Methods: A MEDLINE search of the literature was performed, focusing on papers published in the last two decades. (3) Results and Conclusions: BRCA mutated tumors seem to show a higher response to anthracyclines compared to sporadic tumors and the severity of hand–foot syndrome and mucositis may be a predictive marker of PLD efficacy. CA125 can be a misleading marker of clinical response during treatment with anthracyclines, the response of which also appears to depend on OC histology. Immunochemistry, in particular HER-2 expression, could be of some help in predicting the response to such drugs, and high levels of mutated p53 appear after exposure to anthracyclines and impair their antitumor effect. Finally, organoids from OC are promising for drug testing and prediction of response to chemotherapy. |
format | Online Article Text |
id | pubmed-8998349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89983492022-04-12 Predicting Response to Anthracyclines in Ovarian Cancer Ferrero, Annamaria Borghese, Martina Restaino, Stefano Puppo, Andrea Vizzielli, Giuseppe Biglia, Nicoletta Int J Environ Res Public Health Review (1) Background: Anthracyclines are intriguing drugs, representing one of the cornerstones of both first and subsequent-lines of chemotherapy in ovarian cancer (OC). Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. Prediction of response to anthracyclines is challenging and no markers can predict certain therapeutic success. The current narrative review provides a summary of the clinical and biological mechanisms involved in the response to anthracyclines. (2) Methods: A MEDLINE search of the literature was performed, focusing on papers published in the last two decades. (3) Results and Conclusions: BRCA mutated tumors seem to show a higher response to anthracyclines compared to sporadic tumors and the severity of hand–foot syndrome and mucositis may be a predictive marker of PLD efficacy. CA125 can be a misleading marker of clinical response during treatment with anthracyclines, the response of which also appears to depend on OC histology. Immunochemistry, in particular HER-2 expression, could be of some help in predicting the response to such drugs, and high levels of mutated p53 appear after exposure to anthracyclines and impair their antitumor effect. Finally, organoids from OC are promising for drug testing and prediction of response to chemotherapy. MDPI 2022-04-02 /pmc/articles/PMC8998349/ /pubmed/35409939 http://dx.doi.org/10.3390/ijerph19074260 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ferrero, Annamaria Borghese, Martina Restaino, Stefano Puppo, Andrea Vizzielli, Giuseppe Biglia, Nicoletta Predicting Response to Anthracyclines in Ovarian Cancer |
title | Predicting Response to Anthracyclines in Ovarian Cancer |
title_full | Predicting Response to Anthracyclines in Ovarian Cancer |
title_fullStr | Predicting Response to Anthracyclines in Ovarian Cancer |
title_full_unstemmed | Predicting Response to Anthracyclines in Ovarian Cancer |
title_short | Predicting Response to Anthracyclines in Ovarian Cancer |
title_sort | predicting response to anthracyclines in ovarian cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998349/ https://www.ncbi.nlm.nih.gov/pubmed/35409939 http://dx.doi.org/10.3390/ijerph19074260 |
work_keys_str_mv | AT ferreroannamaria predictingresponsetoanthracyclinesinovariancancer AT borghesemartina predictingresponsetoanthracyclinesinovariancancer AT restainostefano predictingresponsetoanthracyclinesinovariancancer AT puppoandrea predictingresponsetoanthracyclinesinovariancancer AT vizzielligiuseppe predictingresponsetoanthracyclinesinovariancancer AT biglianicoletta predictingresponsetoanthracyclinesinovariancancer |